The Arcturus subvariant stems from the Omicron strain of Covid-19 and is known as XBB.1.16 since it descends from the recombinant variant XBB, which combines two sublineages of Omicron BA.2.

However, there's a new symptom: conjunctivitis. India was the first country to detect Arcturus. The highly contagious and new COVID-19 strain is in at least 24 countries. According to experts ...

Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including mRNA, siRNA, replicon RNA, asRNA, DNA, and gene editing therapeutics.

the MHLW is an important milestone for the saRNA field and the Arcturus/CSL alliance, which has candidates against other variants in phase 3 testing – including the prevailing XBB.1.5 strain ...

Arcturus Therapeutics believes it’s “highly ... run two phase 3 studies of its mRNA vaccine against different strains of bird flu, as well as bring four new influenza vaccines into phase ...

The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by Canaccord Genuity on March 10, 2025. The analyst firm set a price target for $68.00 expecting ARCT to rise to within ...

Explore Arcturus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ARCT. Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer ...

"Arcturus continues to make excellent progress ... for up to 12 months post vaccination against multiple SARS-CoV-2 strains in both younger and older adult age groups versus the mRNA comparator.